Dementia
Authors: Christine Laine
Journal: Annals of Internal Medicine (2008)

In the Clinic1 April 2008DementiaChristine Laine, MD, MPH, David R. Goldman, MD, David M. Blass, MD, and Peter V. Rabins, MD, MPHChristine Laine, MD, MPHSearch for more papers by this author, David R. Goldman, MDSearch for more papers by this author, David M. Blass, MDSearch for more papers by this author, and Peter V. Rabins, MD, MPHSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-7-200804010-01004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.PreventionDementia is defined as a decline in cognitive function from baseline. It is a syndrome caused by a variety of disorders, the most common of which are Alzheimer disease, vascular dementia, Lewy body dementia, and frontotemporal dementia. The incidence and prevalence of dementia increase with age. It is estimated that by the year 2047, more than 9 million Americans will have some form of it (1). Institutionalization is ultimately required for many patients with dementia, and 67% die in nursing homes (2). Although there is currently no ...References1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-42. [PMID: 9736873] Google Scholar2. Mitchell SL, Teno JM, Miller SC, et al. A national study of the location of death for older persons with dementia. J Am Geriatr Soc. 2005;53:299-305. [PMID: 15673356] Google Scholar3. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21: 49-55. [PMID: 10794848] Google Scholar4. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352: 1347-51. [PMID: 9802273] Google Scholar5. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-75. [PMID: 12742805] Google Scholar6. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20. [PMID: 9549720] Google Scholar7. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627-31. [PMID: 11089820] Google Scholar8. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999; 52:971-5. [PMID: 10102414] Google Scholar9. Meyer JS, McClintic KL, Rogers RL, et al. Aetiological considerations and risk factors for multi-infarct dementia. J Neurol Neurosurg Psychiatry. 1988;51:1489-97. [PMID: 3221215] Google Scholar10. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 1994;13: 131-44. [PMID: 8090255] Google Scholar11. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20 Suppl 2:S28-35. [PMID: 1833351] Google Scholar12. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40: 1698-707. [PMID: 2146525] Google Scholar13. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45:1161-8. [PMID: 7783883] Google Scholar14. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987; 107:169-73. [PMID: 2886086] Google Scholar15. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327: 128. [PMID: 12869452] Google Scholar16. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1: e33. [PMID: 17111043] Google Scholar17. Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288: 2123-9. [PMID: 12413371] Google Scholar18. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289: 2651-62. [PMID: 12771112] Google Scholar19. U.S. Preventive Services Task Force. Screening for dementia and other diseases. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996: 531-40. Accessed at www.guideline.gov/summary/summary.aspx?doc_id=3690 on 7 February 2008. Google Scholar20. Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160:2964-8. [PMID: 11041904] Google Scholar21. Barker WW, Luis C, Harwood D, et al. The effect of a memory screening program on the early diagnosis of Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19:1-7. [PMID: 15764864] Google Scholar22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98. [PMID: 1202204] Google Scholar23. Borson S, Scanlan J, Brush M, et al. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15:1021-7. [PMID: 11113982] Google Scholar24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44. [PMID: 6610841] Google Scholar25. Massoud F, Devi G, Moroney JT, et al. The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study. J Am Geriatr Soc. 2000;48:1204-10. [PMID: 11037005] Google Scholar26. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130: 2616-35. [PMID: 17704526] Google Scholar27. van der Cammen TJ, Croes EA, Dermaut B, et al. Genetic testing has no place as a routine diagnostic test in sporadic and familial cases of Alzheimer's disease. J Am Geriatr Soc. 2004;52:2110-3. [PMID: 15571552] Google Scholar28. Hunt LA, Murphy CF, Carr D, et al. Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol. 1997;54:707-12. [PMID: 9193205] Google Scholar29. Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;54: 2205-11. [PMID: 10881240] Google Scholar30. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-14. [PMID: 10784462] Google Scholar31. Qaseem A, Snow V, Cross JT Jr, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2008;148:370-8. Google Scholar32. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Ann Intern Med. 2008;148:379-97. Google Scholar33. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351:2509-18. [PMID: 15590953] Google Scholar34. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000; 356:2031-6. [PMID: 11145488] Google Scholar35. Beversdorf DQ, Warner JL, Davis RA, et al. Donepezil in the treatment of dementia with lewy bodies [Letter]. Am J Geriatr Psychiatry. 2004;12:542-4. [PMID: 15353396] Google Scholar36. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336: 1216-22. [PMID: 9110909] Google Scholar37. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142:37-46. [PMID: 15537682] Google Scholar38. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005;2:541-51. [PMID: 16375657] Google Scholar39. Zubenko GS, Zubenko WN, McPherson S, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003;160:857-66. [PMID: 12727688] Google Scholar40. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10:125-8. [PMID: 11925273] Google Scholar41. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737-46. [PMID: 12860778] Google Scholar42. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86:138-45. [PMID: 1529737] Google Scholar43. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13:233-40. [PMID: 11495397] Google Scholar44. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-86. [PMID: 17548409] Google Scholar45. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43. [PMID: 16234500] Google Scholar46. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210. [PMID: 16505124] Google Scholar47. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-41. [PMID: 16319382] Google Scholar48. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res. 1992;20:150-61. [PMID: 1521671] Google Scholar49. Chan DC, Kasper JD, Black BS, et al. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58:548-54. [PMID: 12807927] Google Scholar50. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090-7. [PMID: 11966383] Google Scholar51. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA. 1996;276:1725-31. [PMID: 8940320] Google Scholar52. Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 1997;52:P159-66. [PMID: 9224439] Google Scholar53. Haupt M, Karger A, Jänner M. Improvement of agitation and anxiety in demented patients after psychoeducative group intervention with their caregivers. Int J Geriatr Psychiatry. 2000; 15:1125-9. [PMID: 11180469] Google Scholar54. Rabins PV, Blacker D, Rover BW, et al. Practice Guideline for the treatment of patients with Alzheimer's disease and other dementias. Supp Am J Psych. 2007;164:25-7. Google Scholar55. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-53. [PMID: 11342678] Google Scholar56. Assessing Care of Vulnerable Elders (ACOVE). ACOVE Quality Indicator Library. Accessed at www.acove.com/QI/Acove.hta on 12 February 2008. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTeaching Medical Student Geriatrics Competencies in 1 Week: An Efficient Model to Teach and Document Selected Competencies Using Clinical and Community Resources 1 April 2008Volume 148, Issue 7Page: ITC4-1KeywordsAlzheimer diseaseCaregiversCognitionDeliriumDementiaElderlyHypertensionMedical risk factorsQuality of lifeSleep ePublished: 1 April 2008 Issue Published: 1 April 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...